What’s Trending?

Facility represents one of the largest commercial-scale operations in the world [...]
Fri, Dec 09, 2022
Source PharmaTimes
Study involves candidate NVD-003 and the treatment of lower limb trauma [...]
Fri, Dec 09, 2022
Source PharmaTimes
Data supports LR 09 as a vital checkpoint inhibitor for treating leukaemia patients [...]
Thu, Dec 08, 2022
Source PharmaTimes
Implantable ARC therapy demonstrates potential to improve blood pressure regulation [...]
Thu, Dec 08, 2022
Source PharmaTimes
CPHI Barcelona 2023
24 - 26 October, 2023, Barcelona, Spain. The global pharma industry was out in full force at CPHI Frankfurt in November with 40,405 executives from 167 countries visiting the 2022 edition of the world-leading pharma industry tradeshow, a huge 75% increase over the number of attendees in 2021. Final visitor numbers [...]
Thu, Dec 08, 2022
Source WorldPharmaNews
Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant. The drug is designed in such a way that natural selection to maintain infectiousness of the virus should also maintain the [...]
Wed, Dec 07, 2022
Source WorldPharmaNews
Pfizer
Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19. PLpro is an essential enzyme, which, along with the main protease [...]
Tue, Dec 06, 2022
Source WorldPharmaNews
An international team of researchers has uncovered a new mechanism that enables cancer cells to move throughout the body, providing a potential new target to stop metastasis, which is responsible for 90 per cent of cancer deaths. In findings published in Nature, the team identifies that cancer cells move faster when [...]
Mon, Dec 05, 2022
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews